The Swiss Times - Swiss News in English

LimmaTech STI Research Awarded $2.2 Million Dollars by CARB-X

  • By The Swiss Times
  • 2 March 2024

LimmaTech Biologics AG receives a $2.2 million boost from CARB-X to combat antibiotic-resistant gonorrhea with a promising vaccine, aiming to alleviate a global health threat.

LimmaTech STI Research Awarded $2.2 Million Dollars by CARB-X
Keystone/SDA – MICHAEL WYKE

LimmaTech Biologics AG, a Swiss company, focusing on a pivotal vaccine against neisseria gonorrhoea claims they have been granted a significant $2.2 million investment from CARB-X.

LimmaTech’s CEO, emphasises the dire need for an efficacious vaccine to combat the escalating drug resistance observed in gonorrhea cases. The proprietary technology behind their vaccine could be a game-changer in the battle against bacterial infectious diseases.

This sexually transmitted infection (STI), ranking as the second most reported globally, affected roughly 82 million people in 2020, leading to severe health consequences like infertility and increased HIV risk. The stealth nature of this disease, often asymptomatic, highlights the hidden health burden it imposes.

LimmaTech’s vaccine aims to counteract the growing menace of antibiotic-resistant strains of Neisseria gonorrhoeae, which have outmaneuvered nearly all antibiotics, leaving ceftriaxone as the sole remaining effective treatment.

The vaccine’s development, aims to induce an immune response across various bacterial strains, a critical factor for ensuring accessibility and affordability in lower-income regions.

Since its establishment in 2016, CARB-X has been instrumental in reinvigorating the stagnant antibiotic pipeline, supporting over 90 R&D projects across 13 countries. 18 projects they have backed lead to clinical trials and the introduction of two diagnostic products to the market.

LimmaTech’s vaccine, is the sixth project funded in the 2022-2023 cycle, exemplifies CARB-X’s ongoing efforts to address critical gaps in the antibacterial science.

The consortium funding this research includes prestigious entities like the U.S. Health Department, Wellcome, and the Novo Nordisk Foundation, among others. This collaborative effort underscores the global commitment to combating the threat of antibiotic-resistant infections.

Most Read

Sunday, April 7 – Round Up

7 April 2024
Sunday, April 7 – Round Up
Switzerland may fund French nuclear projects as it grapples with internal issues in the news this Sunday morning.

Swiss Employers Association: Increase Retirement Ages

8 April 2024
Swiss Employers Association: Increase Retirement Ages
Following the rejection of a pension initiative, the Swiss Employers' Association (SAV) recommends a gradual raise in retirement age to 66.

Diehl Defence Will Develop Drones For Swiss Defence Firm Skysec

12 April 2024
Diehl Defence Will Develop Drones For Swiss Defence Firm Skysec
Diehl Defence collaborates with Skysec Defence under a new agreement to enhance drone defense capabilities for military use.

Zurich VC Lakestar Secures $600 Million In New Funds

12 April 2024
Zurich VC Lakestar Secures $600 Million In New Funds
Lakestar successfully closes two new funds, accumulating $600 million, to advance Europe's digital sovereignty.

Stay in Touch!

Noteworthy

Thai Central Group to Allegedly Takeover KaDeWe
Thai Central Group to Allegedly Takeover KaDeWe
12 April 2024
Leonteq and Raiffeisen Extend Partnership
Leonteq and Raiffeisen Extend Partnership
12 April 2024